Stockholders' Deficit (Details) - USD ($) |
1 Months Ended | 9 Months Ended | 12 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 10, 2021 |
Dec. 10, 2021 |
Nov. 15, 2021 |
Oct. 21, 2021 |
Oct. 01, 2021 |
Jul. 15, 2021 |
Oct. 15, 2020 |
Jan. 14, 2019 |
Aug. 19, 2022 |
May 19, 2022 |
Nov. 15, 2021 |
Jan. 30, 2020 |
Sep. 21, 2018 |
Dec. 31, 2022 |
Sep. 30, 2022 |
Dec. 31, 2021 |
Jan. 31, 2022 |
Dec. 31, 2020 |
|
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Preferred stock, shares authorized | 10,000,000 | 10,000,000 | 10,000,000 | |||||||||||||||
| Preferred stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||
| Common stock, authorized | 750,000,000 | 750,000,000 | ||||||||||||||||
| Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||
| Voting rights | one | one | ||||||||||||||||
| Shares issued | 4,243 | |||||||||||||||||
| Outstanding payables | $ 129,850 | |||||||||||||||||
| Equity incentive plan, description | The vesting period, term and exercise price will be determined at the time of the grant. An aggregate of up to 41,176 of the Company’s common stock was reserved for issuance under the 2018 Plan. On July 15, 2021 the Company’s board of directors increased the number of shares of common stock authorized for grant from 41,176 to 94,118. As of March 31, 2022, the Company has granted and has 85,285 options outstanding, as well as 1,269 shares of restricted common stock issued under the 2018 Plan. | |||||||||||||||||
| Purchase an aggregate, description | the Board of Directors approved the issuance of options to purchase an aggregate of 31,979 shares of common stock to the certain employees of the Company. The options have an exercise price of $17.85 per share with vesting terms of one quarter vesting on June 10, 2022 and the remainder monthly ratably through December 10, 2023. The options will expire on December 11, 2031. The aggregate fair value of $472,975 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 116.90%, (iii) risk free rate of 1.26% (iv) dividend rate of zero, (v) stock price of $17.85, and (vi) exercise price of $17.85. These options were amended on December 30, 2021 adjusting the vesting schedule to vest equally at the end of each quarter in 2022. As the share price had increased on the amendment date, the amendment resulted in an increase to the aggregate fair value of $111,166. The increased fair value along with the unamortized portion of the original fair value will be amortized over the amended vesting schedule. A total of $26,574 was recorded during the year ended December 31, 2021. | the Board of Directors approved the issuance of options to purchase an aggregate of 31,979 shares of common stock to the certain employees of the Company. The options have an exercise price of $17.85 per share with vesting terms of one quarter vesting on June 10, 2022 and the remainder monthly ratably through December 10, 2023. The options will expire on December 11, 2031. The aggregate fair value of $472,975 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 116.90%, (iii) risk free rate of 1.26% (iv) dividend rate of zero, (v) stock price of $17.85, and (vi) exercise price of $17.85. These options were amended on December 30, 2021 adjusting the vesting schedule to vest equally at the end of each quarter in 2022. As the share price had increased on the amendment date, the amendment resulted in an increase to the aggregate fair value of $111,166. The increased fair value along with the unamortized portion of the original fair value will be amortized over the amended vesting schedule. A total of $26,574 was recorded during the year ended December 31, 2021 | the Board of Directors approved the issuance of options to purchase an aggregate of 17,039 shares of common stock to the directors of the Company. The options have an exercise price of $24.65 per share and vest per days in service as members of the board of directors during the quarter, at the end of the quarter with the final quarterly vesting quarter end of December 31, 2022. The options will expire on December 11, 2031. The aggregate fair value of $341,793 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5.04 years, (ii) volatility of 115.8%, (iii) risk free rate of 1.25% (iv) dividend rate of zero, (v) stock price of $24.65, and (vi) exercise price of $24.65. The expense will be amortized over the vesting period and a total of $28,254 was recorded during the year ended December 31, 2021. | the Board of Directors approved the issuance of options to purchase an aggregate of 14,332 shares of common stock to the CEO. The options have an exercise price of $33.15 per share with vesting terms of 3,583 vesting on April 21, 2022 and the remainder monthly ratably through October 21, 2023. The options will expire on October 21, 2031. The aggregate fair value of $372,384 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 4.65 years, (ii) volatility of 113.90%, (iii) risk free rate of 1.22% (iv) dividend rate of zero, (v) stock price of $33.15, and (vi) exercise price of $33.15. These options were amended on December 10, 2021 and December 30, 2021 adjusting the exercise price to $17.85 and the vesting schedule to vest equally at the end of each quarter in 2022. The expense will be amortized over the amended vesting period and a total of $36,667 was recorded during the year ended December 31, 2021. | the Board of Directors approved the issuance of options to purchase an aggregate of 52,990 shares of common stock to an executive and a director. The options have an exercise price of $29.75 per share and vested immediately upon issuance. The options will expire on October 1, 2031. The aggregate fair value of $1,270,188 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 115%, (iii) risk free rate of 0.93% (iv) dividend rate of zero, (v) stock price of $29.75, and (vi) exercise price of $29.75. The expense of 1,270,188 was recorded in full upon issuance. | the Board of Directors approved the issuance of options to purchase an aggregate of 303,390 shares of common stock to certain employees of the Company. The options have an exercise price of $10.2 per share with varying vesting terms through August 10, 2023. The options will expire on August 19, 2027. The aggregate fair value of $2,346,000 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 100.0%, (iii) risk free rate of 3.10% (iv) dividend rate of zero, (v) stock price of $10.2, and (vi) exercise price of $10.2. The expense will be amortized over the vesting period and a total of $2,277,618 was recorded since issuance and through September 30, 2022. | the Board of Directors approved the issuance of options to purchase an aggregate of 12,778 shares of common stock to certain employees of the Company. The options have an exercise price of $26.35 per share with vesting terms of one quarter/half vesting on November 19, 2022 and the remainder monthly ratably through May 19, 2023. The options will expire on May 19, 2032. The aggregate fair value of $271,324 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5 years, (ii) volatility of 115.0%, (iii) risk free rate of 2.80% (iv) dividend rate of zero, (v) stock price of $26.35, and (vi) exercise price of $26.35. The expense will be amortized over the vesting period and a total of $99,491 was recorded since issuance and through September 30, 2022. | the Board of Directors approved the issuance of options to purchase an aggregate of 17,039 shares of common stock to the directors of the Company. The options have an exercise price of $24.65 per share and vest per days in service as members of the board of directors during the quarter, at the end of the quarter with the final quarterly vesting quarter end of December 31, 2022. The options will expire on December 11, 2031. The aggregate fair value of $341,793 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life of 5.04 years, (ii) volatility of 115.8%, (iii) risk free rate of 1.25% (iv) dividend rate of zero, (v) stock price of $24.65, and (vi) exercise price of $24.65. The expense will be amortized over the vesting period and a total of $28,254 was recorded during the year ended December 31, 2021. | the Board of Directors approved the issuance of options to purchase an aggregate of 9,412 shares of common stock to Boris Goldstein. The options have an exercise price of $63.75 per share which will vest ratably on a quarterly basis over a two-year period. The options will expire on January 30, 2029. The aggregate fair value of $51,757 was calculated using the Black-Scholes pricing model with the following assumptions: (i) expected life 10 years, (ii) volatility of 76%, (iii) risk free rate of 1.57% (iv) dividend rate of zero, (v) stock price of $10.2, and (vi) exercise price of $63.75. The expense will be amortized over the vesting period and a total of $23,790 was recorded during the year ended December 31, 2020. | |||||||||
| Stock option remaining value | $ 513,807 | |||||||||||||||||
| Stock based compensation | $ 280,369 | |||||||||||||||||
| Common stock issued | 128 | |||||||||||||||||
| Tax withholdings | 2,168 | |||||||||||||||||
| Expected life (years) | 6 years 18 days | 5 years 6 months | ||||||||||||||||
| Volatility rate | 100.00% | 98.00% | ||||||||||||||||
| Risk free interest rate | 3.50% | 4.00% | ||||||||||||||||
| Dividend rate | 0.00% | 0.00% | ||||||||||||||||
| Share price | $ 25.5 | $ 10.2 | ||||||||||||||||
| Previously Reported [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Common stock, authorized | 200,000,000 | 200,000,000 | ||||||||||||||||
| Minimum [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Expected life (years) | 6 months 18 days | 3 months | ||||||||||||||||
| Volatility rate | 92.00% | |||||||||||||||||
| Risk free interest rate | 2.30% | 3.30% | ||||||||||||||||
| Exercise price | $ 28.05 | $ 28.05 | ||||||||||||||||
| Maximum [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Expected life (years) | 1 year 3 months | 11 months 12 days | ||||||||||||||||
| Volatility rate | 100.00% | |||||||||||||||||
| Risk free interest rate | 3.00% | 4.00% | ||||||||||||||||
| Exercise price | $ 30.6 | $ 30.6 | ||||||||||||||||
| Common Stock [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Shares outstanding | 1,240,094 | 590,857 | ||||||||||||||||
| 2018 Equity Incentive Plan [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Common stock are reserved for issuance | 41,176 | |||||||||||||||||
| Option outstanding | 21,176 | |||||||||||||||||
| Issue of shares for the services | 3,929 | |||||||||||||||||
| 2018 Equity Incentive Plan [Member] | Minimum [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Common stock authorized for grant | 3,500,000 | |||||||||||||||||
| 2018 Equity Incentive Plan [Member] | Maximum [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Common stock authorized for grant | 8,000,000 | |||||||||||||||||
| Option [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Remaining stock options will be amortized | $ 1,266,050 | |||||||||||||||||
| Non-Executive Officer [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Granted restricted shares | 3,437 | |||||||||||||||||
| Grant fair value per share | $ (1.67) | |||||||||||||||||
| Amortized vesting period value | $ 487,931 | |||||||||||||||||
| Board of Directors [Member] | Option [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Purchase of aggregate share | 9,412 | |||||||||||||||||
| Aggregate fair value of options | $ 51,757 | |||||||||||||||||
| Expected life (years) | 10 years | |||||||||||||||||
| Volatility rate | 76.00% | |||||||||||||||||
| Risk free interest rate | 1.57% | |||||||||||||||||
| Dividend rate | 0.00% | |||||||||||||||||
| Share price | $ 10.2 | |||||||||||||||||
| Exercise price | $ 63.75 | |||||||||||||||||
| Boris Goldstein [Member] | Option [Member] | ||||||||||||||||||
| Stockholders' Deficit (Textual) | ||||||||||||||||||
| Description of options vesting period | The options have an exercise price of $63.75 per share which will vest ratably on a quarterly basis over a two-year period. | |||||||||||||||||
| Expiration date | Jan. 30, 2029 | |||||||||||||||||